VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial

ALX Oncology Holdings Executive Compensation (FY25)

ALXO · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Jason Lettmann
Latest say-on-pay support
=
June 10, 2026
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The ALX Oncology Holdings brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 1, 2026Latest filing (8-K): June 11, 2026
8 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
ALX Oncology Holdings brief$500Get the executive brief
Velarion Intel, one year, every company
179 figures on this page: 174 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Jason Lettmann: $6,640,830 → $2,470,844 (62.8% lower)
Say-on-pay support: 71.7% → 86.2% (14.5 points higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is ALX Oncology Holdings' chief executive and what were they paid?
Total compensation for Jason Lettmann, Chief Executive Officer, came to $2,470,844 in fiscal 2025. Lettmann's total was 62.8% lower than the $6,640,830 reported for fiscal 2024.
What was ALX Oncology Holdings' say-on-pay result?
The say-on-pay proposal drew 86.2% of votes cast for or against in favor at the meeting held June 10, 2026 for fiscal 2025.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jaume Pons
President, Chief Scientific Officer and former Chief Executive Officer
◇—◇◇◇——◇
Sophia Randolph
Chief Medical Officer
◇—◇◇◇——◇
Peter Garcia
Chief Financial Officer
◇—◇◇◇——◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jason Lettmann
Chief Executive Officer
◇——◇◇—◇◇
Jaume Pons
President, Chief Scientific Officer and former Chief Executive Officer
◇—◇◇◇——◇
Sophia Randolph
Chief Medical Officer
◇—◇◇◇——◇
Peter Garcia
Chief Financial Officer
◇—◇◇◇——◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jason Lettmann
Chief Executive Officer
◇—◇◇◇——◇
Sophia Randolph
Former Chief Medical Officer
Departed during or after this year
◇—◇◇——◇◇
Jaume Pons
Former President and Chief Scientific Officer
Departed during or after this year
◇—◇◇◇——◇
Peter Garcia
Former Chief Financial Officer
Departed during or after this year
◇—◇◇——◇◇
Shelly Wong
Senior Vice President, Finance and Chief Accounting Officer
◇◇◇◇◇——◇
Shelly Pinto
Senior Vice President, Finance and Chief Accounting Officer
◇◇◇◇◇——◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Jason Lettmann
Chief Executive Officer
◇——◇◇——◇
Harish Shantharam
Chief Financial Officer
◇——◇◇——◇
Jaume Pons
Former President and Chief Scientific Officer
Departed during or after this year
◇——◇——◇◇
Shelly Wong
Senior Vice President, Finance and Chief Accounting Officer
◇——◇◇——◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Harish ShantharamOption◇—◇January 20, 2035
Option◇—◇October 13, 2035
Option◇—◇April 10, 2035
Jason LettmannOption◇—◇October 13, 2035
Option◇—◇September 7, 2033
Option◇—◇January 20, 2035
Option◇—◇April 10, 2035
Option◇—◇December 1, 2031
Option◇—◇February 13, 2034
RSU◇◇——
RSU◇◇——
Shelly WongOption◇—◇October 13, 2035
Option◇—◇December 1, 2031
Option◇—◇April 10, 2035
Option◇—◇January 20, 2035
Option◇—◇February 13, 2034
Option◇—◇July 24, 2033
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇August 4, 2032
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Alan Sandler, M.D
◇————◇◇
Barbara Klencke, M.D
◇—◇——◇◇
Corey Goodman, Ph.D
Board chair
◇—◇———◇
Rekha Hemrajani
◇—◇———◇
Scott Garland
◇—◇———◇
Chris Takimoto, M.D., Ph.D., F.A.C.P
◇—◇———◇
Daniel Curran, M.D
◇—◇———◇
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 10, 2026=◇◇◇
2024June 11, 2025=◇◇◇
2023June 12, 2024=◇◇◇
2022June 16, 2023=◇◇◇
2021June 14, 2022=◇◇◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Jason Lettmann (Chief Executive Officer), FY2025 total compensation $2,470,844 (base salary $724,500) [exec_comp, SEC accession 0001193125-26-163936, filed 2026-04-20]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when ALX Oncology Holdings files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact ALX Oncology Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether ALX Oncology Holdings' disclosed peer group is defensible, who names ALX Oncology Holdings back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
179 figures on this page: 174 cited to the filing that reported them, 5 calculated from figures it prints.
174 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001193125-26-267472
    Item 5.07 Submission of matters to a vote of security holders.
  2. 0001193125-26-163936
    Director Compensation · Outstanding Equity Awards at 2025 Year-End · Summary Compensation Table
  3. 0000950170-25-085364
    Item 5.07 Submission of matters to a vote of security holders.
  4. 0000950170-25-056291
    Summary Compensation Table
  5. 0000950170-24-074258
    Item 5.07 Submission of matters to a vote of security holders.
  6. 0000950170-24-046410
    Summary Compensation Table
  7. 0000950170-23-028787
    Item 5.07 Submission of matters to a vote of security holders.
  8. 0001193125-22-175515
    Item 5.07. Submission of matters to a vote of security holders.
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “ALX Oncology Holdings executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ALXO (accessed 2026).
Short form: data: Velarion

The ALX Oncology Holdings brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
8 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about ALX Oncology Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy